Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/ S-A vaccines halted in Japan

Separate vaccines from sanofi-aventis and Pfizer have had their use suspended in Japan following the deaths of four children

Separate vaccines from sanofi-aventis (S-A) and Pfizer have had their use suspended in Japan following the deaths of four children.

S-A's ActHIB, to protect against Haemophilus influenzae type b, and Pfizer's Prevenar to prevent against pneumococcal disease such as pneumonia and meningitis, have been suspended by Japan's Health Ministry while the causes of deaths of four inoculated children are investigated.

According to the Associated Press, four children, age 2 years old or under, died between March 2 and March 4, with the deaths occurring within a three day period of the vaccines administration.

Over one million children have been inoculated in Japan since ActHIB was launched in the country in December 2008 and Prevenar started to be used in 2009.

The suspension follows a 2009 incident where authorities suspended the use of a batch of Prevenar in the Netherlands after the deaths of three children inoculated with the vaccine.

Authorities later decided there was no correlation between the deaths and the vaccinations.

7th March 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics